Skip to main content
SpringerLink
Log in

Cancer-related anorexia/cachexia an ongoing challenge despite an increasing range of drug choices

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mantovani G, Macciò A, Massa E, et al. Managing cancer-related anorexia/cachexia. Drugs 2001; 61(4): 499–514

    Article  PubMed  CAS  Google Scholar 

  2. Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol 2000; 27: 64–8

    PubMed  CAS  Google Scholar 

  3. Billingsly KG, Alexander HR. The pathophysiology of cachexia in advanced cancer and AIDS. In: Bruera E, Higginson I, editors. Cachexia-anorexia in cancer patients. Oxford: Oxford University Press, 1996: 1–22

    Google Scholar 

  4. Haskell CM, Mendoza E, Pisters KM, et al. Phase II study of intravenous adenosine triphosphate (ATP) in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 1998; 16: 81–5

    Article  PubMed  CAS  Google Scholar 

  5. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 1999; 10: 857–9

    Article  PubMed  CAS  Google Scholar 

  6. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55: 675–88

    Article  PubMed  CAS  Google Scholar 

  7. Mantovani G, Macciò A, Esu S, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997; 33: 602–7

    Article  PubMed  CAS  Google Scholar 

  8. Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Semin Oncol 1998; 25 Suppl. 6: 35–44

    PubMed  CAS  Google Scholar 

  9. Lissoni P, Ardizzoia A, Perego MS, et al. Inhibition of tumor necrosis factor-alpha secretion by pentoxyfylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. J Biol Regul Homeost Agents 1993; 7: 73–5

    PubMed  CAS  Google Scholar 

  10. Wigmore SJ, Ross JA, Falconer JS et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12 Suppl. 1: S27–30

    PubMed  CAS  Google Scholar 

  11. Wigmore SJ, Falconer JS, Plester CE, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995; 72: 185–8

    Article  PubMed  CAS  Google Scholar 

  12. McMillan DC, O’Gorman P, Fearon KC, et al. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997; 76: 788–90

    Article  PubMed  CAS  Google Scholar 

  13. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994 1; 54: 5602–6

    Google Scholar 

  14. Masferrer JL, Leahy KM, Kohi AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–11

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cancer-related anorexia/cachexia an ongoing challenge despite an increasing range of drug choices. Drugs Ther. Perspect 17, 12–15 (2001). https://doi.org/10.2165/00042310-200117220-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117220-00004

Keywords

Search

Navigation